Grace Therapeutics, Inc. (GRCE)
| Market Cap | 32.73M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -5.98M |
| Shares Out | 15.47M |
| EPS (ttm) | -0.38 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 571,782 |
| Open | 2.110 |
| Previous Close | 2.160 |
| Day's Range | 2.040 - 2.150 |
| 52-Week Range | 1.790 - 5.180 |
| Beta | 0.69 |
| Analysts | Strong Buy |
| Price Target | 8.00 (+278.25%) |
| Earnings Date | Feb 12, 2026 |
About GRCE
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company’s lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for GRCE stock is "Strong Buy" and the 12-month stock price target is $8.0.
News
Grace Therapeutics Stock Falls As FDA Declines To Approve Brain Hemorrhage Drug
Grace Therapeutics Inc. (NASDAQ:GRCE) shares are down during Friday's premarket session following a regulatory update regarding its New Drug Application (NDA) for GTx-104.
US FDA declines to approve Grace Therapeutics' drug for a type of stroke
Grace Therapeutics said on Thursday the U.S. Food and Drug Administration declined to approve its drug for a rare type of stroke.
Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104
FDA Issued Complete Response Letter Citing Outstanding Items Related to Chemistry, Manufacturing, and Controls and Non-Clinical Information
Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026
PRINCETON, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, no...
Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences
PRINCETON, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, no...
Grace Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
GTx-104, an IV formulation of nimodipine for aSAH, demonstrated superior dose compliance, fewer hypotensive events, and better recovery outcomes versus oral forms in the STRIVE-ON trial. Regulatory review is progressing, with launch preparations focused on key hospitals and broad market education.
Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
PRINCETON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, nov...
Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update
FDA Established April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Phase 3 STRIVE-ON ...
Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference
PRINCETON, N.J., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, nov...
Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update
Announced U.S. Food and Drug Administration (FDA) Acceptance for Review of New Drug Application (NDA) for GTx-104 FDA Established April 23, 2026 as PDUFA Target Date for Review of Submission Seeking A...
Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual Meeting
PRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, nov...
Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review
PRINCETON, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, nov...
Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting
PRINCETON, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, no...
Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104
Grant of First Method of Use Patent Adds New Pillar to Grace's Multi-layered Intellectual Property and Potential Market Exclusivity Protection Patent Coverage Extended to 2043 PRINCETON, N.J., Sept. 1...
Grace Therapeutics Transcript: Q3 Investor Summit Group Virtual Conference 2025
A novel IV amlodipine formulation for subarachnoid hemorrhage demonstrated superior clinical and economic outcomes over oral therapy in a pivotal trial. With strong patent protection, focused commercialization, and FDA review underway, a major catalyst is expected by April 2026.
Grace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference
PRINCETON, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, no...
Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104
FDA Establishes April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Comprehensive Data...
Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update
Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for GTx-104 Seeking Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH)
Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104
Submission Seeks Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Comprehensive Data Package Includes Positive Results from Phase 3 STRIVE-ON Safety Tria...
Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update
Held Type C meeting with FDA on Planned New Drug Application (NDA) Submission, Including Clinical, Non-clinical, and Chemistry, Manufacturing, and Control (CMC) Requirements NDA On Track for Submissio...
Grace Therapeutics to Participate in the 2025 BIO International Conference
PRINCETON, N.J., June 13, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, nov...
Grace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104
PRINCETON, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, no...
Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors
BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugebo...
Grace Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference
GTX-104, an IV nimodipine, demonstrated superior safety, neurological outcomes, and pharmacoeconomic benefits over oral nimodipine in subarachnoid hemorrhage. NDA submission is planned for mid-2024, with commercialization targeting high-volume stroke centers.
Grace Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
PRINCETON, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) formerly Acasti Pharma Inc. (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GT...